MenB Vaccine
Meningococcal disease (serogroup B) · Bacterial meningitis · Meningococcemia
Meningococcal serogroup B is now the dominant serogroup causing meningococcal disease in US adolescents and young adults (30–40% of cases). The same devastating clinical picture as other serogroups — rapid-onset bacterial meningitis or meningococcemia, with 10–15% mortality and 20% permanent disability rate.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →The risk-benefit balance in your specific scenario suggests a detailed conversation with your child's provider before deciding.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Meningococcal serogroup B is now the dominant serogroup causing meningococcal disease in US adolescents and young adults (30–40% of cases). The same devastating clinical picture as other serogroups — rapid-onset bacterial meningitis or meningococcemia, with 10–15% mortality and 20% permanent disability rate.
Identical to meningococcal disease generally — potential for death within 24 hours, limb amputation, deafness, and neurological damage. University campuses have experienced cluster outbreaks requiring emergency vaccination campaigns.
🛡️ Vaccine Effectiveness
Effectiveness estimates are 63–73% based on post-licensure real-world studies — lower than many vaccines but meaningful for a disease with no other prevention option. Immunity wanes within 1–2 years; additional doses may be needed for ongoing high-risk exposure.
The polysaccharide structure of MenB makes it harder to generate durable immune responses compared with conjugate vaccines. Vaccine effectiveness varies by study and outbreak setting.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Category B recommendation: shared clinical decision-making for ages 16–23. Strongly recommended during outbreaks and for patients with complement deficiencies, functional asplenia, or eculizumab use.
⚖️ Benefits vs. Considerations
✓ Benefits
- Only vaccine that protects against serogroup B — now the dominant cause of teen/young adult meningococcal disease in the US
- UK infant program showed significant reduction in MenB disease
- Provides some protection against the most feared adolescent infectious disease
- Can be co-administered with MenACWY for complete meningococcal coverage
↕ Considerations
- Category B (not universally recommended) in the US — only shared decision-making
- Lower effectiveness (63%) than most vaccines
- Most reactogenic adolescent vaccine — significant pain, fever, and fatigue common
- Short duration of immunity — may wane within 1–2 years
- Limited long-term safety and effectiveness data (only licensed since 2014–2015)
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The ACIP deliberately chose not to give a Category A (universal) recommendation, instead issuing a Category B recommendation for individual shared decision-making — an unusual move reflecting genuine uncertainty about population-level benefit vs. burden. The decision acknowledged that at current disease rates, mass vaccination would prevent very few cases while exposing millions to a reactogenic vaccine (Mbaeyi et al., 2019).
- Post-licensure effectiveness data from real-world outbreaks has been mixed — some college outbreaks occurred in vaccinated individuals, and effectiveness in outbreak settings may differ from the 63% population estimate (Pelton et al., 2021).
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Real-world effectiveness estimates range from 50–73% across different studies and outbreak settings — substantial uncertainty
- Optimal dose spacing and need for boosters not well-established
- Long-term duration of protection — insufficient data beyond 5 years
- Cost-effectiveness at population level given low disease incidence and vaccine reactogenicity
💉 Related Vaccines
Vaccines often given together or covering related diseases.
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.